Jill Durrant
Impact in
- Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
-
- Acute Lymphoblastic Leukemia research
Papers in
-
- Acute Lymphoblastic Leukemia research 15
- Hematology 12
- Chronic Myeloid Leukemia Treatments 9
- Acute Myeloid Leukemia Research 4
- Co-authors
- Emma Hall (2 shared papers)Anthony H. Goldstone (5 shared papers)G Harrison (3 shared papers)Martin S. Tallman (8 shared papers)H. G. Prentice (5 shared papers)Alan K. Burnett (6 shared papers)Jacob M. Rowe (6 shared papers)Mark R. Litzow (5 shared papers)
- Journals
- Blood (8 papers)British Journal of Haematology (4 papers)Age and Ageing (1 paper)Journal of Clinical Oncology (1 paper)British Journal of Cancer (1 paper)
- Partner nations
- United KingdomUnited StatesIsrael
In The Last Decade
Jill Durrant
19 papers receiving 1.4k citations
Jill Durrant's Hit Papers
Peers
Comparison fields: 5 of 56
- Hematology 1.0k
- Public Health, Environmental and Occupational Health 1.2k
- Genetics 232
- Pediatrics, Perinatology and Child Health 339
- Oncology 226
Countries citing papers authored by Jill Durrant
This map shows the geographic impact of Jill Durrant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jill Durrant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jill Durrant more than expected).
Fields of papers citing papers by Jill Durrant
This network shows the impact of papers produced by Jill Durrant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jill Durrant. The network helps show where Jill Durrant may publish in the future.
Co-authors
The 25 scholars most cited alongside Jill Durrant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) Hit paper breakdown → | 2007 | 579 |
| 2 | 1997 | 199 | |
| 3 | 2004 | 152 | |
| 4 | 1998 | 139 | |
| 5 | 1976 | 123 | |
| 6 | 1976 | 78 | |
| 7 | 1977 | 59 | |
| 8 | 2003 | 49 | |
| 9 | 1986 | 31 | |
| 10 | Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL trial (MRC UKALL XII/ECOG E2993). | 2001 | 26 |
| 11 | 1976 | 25 | |
| 12 | Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993) | 2001 | 22 |
| 13 | 2004 | 13 | |
| 14 | The outcome of 267 Philadelphia positive adults in the international UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years. | 2003 | 10 |
| 15 | 2006 | 6 | |
| 16 | 2004 | 6 | |
| 17 | ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. | 2005 | 5 |
| 18 | XII/ECOG E2993 of more than 1500 patients from the international ALL trial: MRC UKALL Induction therapy for adults with acute lymphoblastic leukemia: results | 2008 | 5 |
| 19 | Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 trial. | 2003 | 1 |
About Jill Durrant
Jill Durrant is a scholar working on Public Health, Environmental and Occupational Health, Hematology, Pediatrics, Perinatology and Child Health, Genetics and Molecular Biology, having authored 19 papers that have together received 1.5k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (15 papers), Chronic Myeloid Leukemia Treatments (9 papers), Acute Myeloid Leukemia Research (4 papers), Childhood Cancer Survivors' Quality of Life (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), Hermeneutics and Narrative Identity (1 paper), Epigenetics and DNA Methylation (1 paper) and DNA Repair Mechanisms (1 paper). The work is most often cited by research in Hematology (1.0k citations), Public Health, Environmental and Occupational Health (1.2k citations), Genetics (232 citations), Pediatrics, Perinatology and Child Health (339 citations) and Oncology (226 citations). Jill Durrant has collaborated with scholars based in United Kingdom, United States and Israel. Frequent co-authors include Emma Hall, Anthony H. Goldstone, G Harrison, Martin S. Tallman, H. G. Prentice, Alan K. Burnett, Jacob M. Rowe, Mark R. Litzow, Raj Chopra and Lorna M. Secker‐Walker. Their work appears in journals such as Blood, British Journal of Haematology, Age and Ageing, Journal of Clinical Oncology and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.